Novel long noncoding RNA LINC02820 augments TNF signaling pathway to remodel cytoskeleton and potentiate metastasis in esophageal squamous cell carcinoma
© 2022. The Author(s)..
Esophageal squamous cell carcinoma (ESCC) is one of the most common malignant tumors in China. However, there are no targets to treat ESCC because the molecular mechanism behind the cancer is still unclear. Here, we found a novel long noncoding RNA LINC02820 was upregulated in ESCC and associated with the ESCC clinicopathological stage. Through a series of functional experiments, we observed that LINC02820 only promoted the migration and invasion capabilities of ESCC cell lines. Mechanically, we found that LINC02820 may affect the cytoskeletal remodeling, interact with splice factor 3B subunit 3 (SF3B3), and cooperate with TNFα to amplify the NF-κB signaling pathway, which can lead to ESCC metastasis. Overall, our findings revealed that LINC02820 is a potential biomarker and therapeutic target for the diagnosis and treatment of ESCC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Cancer gene therapy - 30(2023), 2 vom: 10. Feb., Seite 375-387 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Jing [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 22.02.2023 Date Revised 17.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41417-022-00554-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348711506 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348711506 | ||
| 003 | DE-627 | ||
| 005 | 20231226040911.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41417-022-00554-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1162.xml |
| 035 | |a (DE-627)NLM348711506 | ||
| 035 | |a (NLM)36357564 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Jing |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel long noncoding RNA LINC02820 augments TNF signaling pathway to remodel cytoskeleton and potentiate metastasis in esophageal squamous cell carcinoma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.02.2023 | ||
| 500 | |a Date Revised 17.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a Esophageal squamous cell carcinoma (ESCC) is one of the most common malignant tumors in China. However, there are no targets to treat ESCC because the molecular mechanism behind the cancer is still unclear. Here, we found a novel long noncoding RNA LINC02820 was upregulated in ESCC and associated with the ESCC clinicopathological stage. Through a series of functional experiments, we observed that LINC02820 only promoted the migration and invasion capabilities of ESCC cell lines. Mechanically, we found that LINC02820 may affect the cytoskeletal remodeling, interact with splice factor 3B subunit 3 (SF3B3), and cooperate with TNFα to amplify the NF-κB signaling pathway, which can lead to ESCC metastasis. Overall, our findings revealed that LINC02820 is a potential biomarker and therapeutic target for the diagnosis and treatment of ESCC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a RNA, Long Noncoding |2 NLM | |
| 700 | 1 | |a Huang, Tie-Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Mei, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Fei-Fei |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, De-Huan |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Li-Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Bao-Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Mei-Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jiang-Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Shu-Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Qian, Chao-Nan |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Bi-Jun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer gene therapy |d 1997 |g 30(2023), 2 vom: 10. Feb., Seite 375-387 |w (DE-627)NLM075187256 |x 1476-5500 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2023 |g number:2 |g day:10 |g month:02 |g pages:375-387 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41417-022-00554-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2023 |e 2 |b 10 |c 02 |h 375-387 | ||